Bisphosphonates are considered first-line agents in the treatment of postmenopausal osteo-porosis based on extensive experience of use, safety, and proven efficacy in reducingvertebral, non-vertebral and femur fractures. However, post-marketing reports based onthe treatment of millions of patients/year over lengthy periods of time have revealed theoccurrence of initially unexpected adverse effects, such as oste...